www.deccanherald.com
Covaxin shows robust safety, immunogenicity in 2-18-year-olds: Bharat Biotech reveals clinical trial data | Deccan Herald
Bharat Biotech International Limited (BBIL) said that its Covid-19 vaccine has demonstrated “robust safety and immunogenicity” in trials for 2-18-year-olds. The Hyderabad-based vaccine maker said that neutralising antibodies in children were found to
